AQST Q4 2024 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$12M-10.1% YoY

Gross Profit

$7M61.9% margin

Operating Income

-$14M-114.4% margin

Net Income

-$17M-143.7% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-12.4%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$101M

Total Liabilities

$162M

Stockholders' Equity

-$60M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$13M	-10.1%
Gross Profit	$7M	$9M	-13.8%
Operating Income	-$14M	-$4M	-247.2%
Net Income	-$17M	-$8M	-110.3%

Revenue Segments

Manufacture and Supply Revenue

$19M59%

License and Royalty Revenue

$12M38%

Co-Development and Research Fees

$1M3%

Geographic Segments

UNITED STATES

$19M59%

Non-US

$13M41%